April 21, 2020 -- MilliporeSigma is expanding its BioReliance viral and gene therapy service offering with a second commercial manufacturing facility in Carlsbad, CA. The $110 million facility is set to open in 2021.
MilliporeSigma's expansion will help researchers produce at a scale that ensures these therapies reach more patients in need. Image courtesy of Merck.
MilliporeSigma previously invested in commercial viral and gene therapy manufacturing in 2016 with an initial Carlsbad facility. This site has 16 molecular viral bulk manufacturing cleanroom suites with single-use equipment and two fill/finish suites for gene therapy, viral vaccine, and immunotherapy products.
The new 140,000-sq-ft facility will support single-use viral and gene therapy production at the 1,000-liter scale. The expansion will add 11 suites for various manufacturing steps and nearly double the company's production capacity. The new site will help MilliporeSigma expand contract development and manufacturing services to the viral and gene therapy marketplace, the company said.
Copyright © 2020 scienceboard.net